Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. GISTs can be distinguished from true smooth muscle or neural tumors by the expression of the KIT receptor tyrosine kinase (CD117). Conventional chemotherapy and radiotherapy are ineffective in treating cases of metastatic or recurrent GIST.
Objective response assessment is important in order to be able to describe the treatment effect of anticancer drugs. Diagnostic imaging provides the opportunity for objectivity and standardization.
In 1979, the World Health Organization (WHO) first defined criteria for the assessment of tumor response, and reported the results of cancer treatment in a consistent manner. Due to various discrepancies and interpretive variations in the WHO criteria, the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 was introduced in 2000. Both sets of criteria rely on determining the impact of treatment by following changes in anatomical measurements of tumors. However, the WHO criteria do not mention minimum lesion size or the number of lesions to be monitored in patients with multiple lesions, nor do they consider the type of imaging modality that should be used*hence the need for establishing RECIST.
Several drawbacks of RECIST soon became apparent, however. In lymph nodes, the metastatic lesion is usually not visualized at imaging, but the enlargement of a lymph node is used as an indicator of metastasis. An enlarged adrenal lesion is often seen when a computed tomography (CT) or magnetic resonance imaging (MRI) scan is performed. Very often, such a lesion just represents an adenoma. RECIST does not specify which imaging criteria should be used to define lymph nodes or adrenal glands that contain metastases. Furthermore, when lymph nodes and adrenal glands remain visible, their mere presence indicates that the treatment result cannot be categorized as complete response. Bone metastasis is often the only metastatic site in some patients with breast or prostatic cancer. Bone metastases are defined as non-target lesions*these patients would not be enrolled in experimental studies that require measurable lesions according to RECIST. Responding metastases may become more sclerotic without a decrease or even an increase in size. RECIST only applies for measurement of tumor size in one plane. A volumetric approach may be the most reliable measurement to reflect real changes in size. In RECIST, the vascular phases that should be used are not specified. Some tumors generate hypervascular liver metastases and other tumors hypovascular metastases. Moreover, after treatment, the optimal contrast medium (CM) phase of enhancement of liver metastases may shift during follow-up studies. RECIST does not take into account changes in attenuation at CT or signal intensity at MR imaging when lesions are followed up during or after treatment.
The newly introduced version of RECIST (RECIST 1.1) resolves several problems associated with RECIST 1.0, but major problems in terms of response evaluation of treatment persist. Sometimes size is inversely correlated with treatment effect. For example, it is well known that liver metastases from testicular tumors just receiving traditional chemotherapy may become larger after successful treatment. This phenomenon is much more pronounced in GISTs receiving targeted treatment. In GIST, CM enhancement may decrease as a positive response to treatment even though the size of the tumor is unchanged. Furthermore, in GIST, the appearance of a nodule-within-a-mass pattern without a corresponding change in tumor size is the most important indication of progression.
These problems are highlighted in the review of GIST in this issue of Acta Radiologica, (1) which is highly recommended reading. As stated in the review, positron emission tomography (PET) has been found to be highly sensitive in detecting early response and to have a predictive value in the longterm response to imatinib treatment. Other imaging modalities, such as functional CT (perfusion CT) and contrast-enhanced ultrasound (CEUL), have demonstrated that these imaging modalities are also highly promising in the evaluation of the targeted treatment of GIST. Now and in the very near future, many more tumor types other than GIST will receive targeted treatment regimes, and promising results in several ACTA RADIOLOGICA tumor types have already been published. Even the revised RECIST criteria (with only morphological measurements) cannot meet the need for a more sophisticated means of response evaluation of cancer therapy in solid tumors. In general, functional imaging in several modalities such as US, CT, MRI, and PET are evolving so fast that it is hard to evidence a method before new opportunities arrive in the targeted therapy of cancer.
One has to remember that the RECIST criteria were developed for following up treatment response of solid tumors receiving systemic therapy only. However, the optimal treatment of different kinds of cancers at many oncologic centers now combines systemic treatment with local invasive treatments, and thus the RECIST criteria cannot be met.
As stated in version 1.1 of RECIST, functional imaging is promising but evidence-based studies are needed. The availability of such procedures worldwide is not great. However, new and modified techniques are rapidly emerging, and we cannot wait another 9 years for the next revision, which has to be much more sophisticated and detailed than version 1.1.
